11:00pm (EST)
1. Market Summary
2. Halozyme Therapeutics (HALO) – Ready to Pop or Drop?
3. Earnings
4. Weekly Wrap Portfolio Update
5. Week Ahead
(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section.)
= = = = = = = = = = = = = = =
1. Market Summary
The bulls recorded their second-straight weekly win despite a weak start to 4Q earnings season and weaker-than-expected U.S. economic news. However headlines from Europe were mostly positive (except for Friday) as some of the bond auctions went well and Tech and the Financial stocks put in a strong week leaving the bears befuddled.
Monday’s action was flat as traders awaited Alcoa’s (AA, $9.80, down $0.13) earnings report after the bell which came in better-than-expected on some fronts. Although the company missed Wall Street’s estimates by a penny (excluding write-offs), sales came in above expectations and they announced global demand would come in at 7% which was ahead of forecasts.
This set the stage for Tuesday’s rally as commodities did well, along with the Financial stocks which took another leg higher. Tech was the star as the Nasdaq surged 1% higher to close above 2,700 for the first time since November.
Wednesday was a rest day as the market seemed on hold ahead of key events on Thursday. Although the major indexes traded in a tight range, support held following a pullback at the open before ending mixed. The S&P and Tech paced the gains while the Dow ended the day down a baker’s dozen.
Futures were pointing towards a strong start on Thursday following successful bond auctions from Italy and Spain. However, sentiment quickly changed once the U.S. unemployment figures were released. The good news was Initial Claims stayed under 400,000 and by lunchtime, the market had made its way into positive territory where is coasted higher into the close.
Friday’s action was all about JPMorgan’s (JPM, $35.92, down $0.93) 4Q earnings which were announced before the bell. The company matched expectations but missed on revenues which weighed on the Financial stocks and the market in general. We mentioned the run-up the sector was having and the expectations for an earnings beat were already baked into the cake as shares fell nearly 3% for the session after touching a low of $35.13. It was another case of buy the rumor, sell the news. However, the bigger story of the day turned out to be Standard & Poor’s ratings downgrade of Europe after the bell.
The Dow dropped nearly 50 points, or 0.4%, to end the week at 12,422. The blue-chips traded down to 12,312 but held short-term support. The bounce off the lows still keeps 12,575-12,600 in play but 12,750-12,800 will be hard to tackle if Q4 earnings don’t improve and if Europe flares up again. If the index closes below 12,350-12,300 then 12,200 and 12,000 could come into play. We said last week a bearish trend would develop if we fall below 11,800 so keep that on the backburner. The Dow started Monday at 12,359 and ended with a gain of 62 points, or 0.5%. YTD the index is up 205 points, or 1.7%.
The S&P 500 gave back a six-pack, or 0.5%, to settle at 1,289. The index kissed a low of 1,277 on Friday but was able to hold the 1,275 level. We got a run to 1,300 like we predicted and 1,325 is still within reach but we will need a close above this level to keep the momentum going for January. A break below 1,275 could cause a retest of 1,250 and then 1,200. Below that, we would start loading up on put options. For the week, the S&P advanced a 12-pack, or 0.9%, after beginning at 1,277 and is up 32 points, or 2.5%, for the year.
The Nasdaq fell 14 points, or 0.5%, to finish at 2,710. We said last week Tech looked “poised to test 2,700-2,750” and the high on Thursday came in at 2,726 which was right in the middle. There are some big-name Tech companies reporting this week so the bulls will need meet-and-beat numbers if they plan to challenge the 52-week high of 2,887. The low for the week was 2,662 and we have outlined support at 2,600-2,550 if the 2,700 level falls. The Nasdaq was at 2,674 to start Monday’s session and was the strongest of the 3 indexes after popping 36 points, or 1.4%, by Friday’s close. For 2012, Tech is up 105 points, or 4%.
The S&P Volatility Index ($VIX, 20.91, up 0.44) was flat for the week and we were looking for a break below 20 on a continued rally. The VIX traded down to 20.05 on Tuesday’s pop and 20.46 on Thursday’s rally and we are still expecting mid-teens if the momentum continues. The high for the week was 22.03 on Thursday’s opening drop and 22.43 on Friday’s lows. We continue to watch 22.50 which is “resistance” for the bears. A move above 25 would signal a short-term top in the S&P 500. For new subscribers, a rising VIX is bearish while a falling VIX is bullish.
The Russell 2000 declined 6 points, or 0.8%, and was last seen at 766. The small-cap index was able clear our 750 target on Monday which we said was key for a continued rally. The index traded to a high of 770 on Thursday’s pop and could challenge 800 on continued strength if 775 is cleared on the close this week. A break below 750 would be negative and could lead to a test down to 720. A break below this level would be bearish. The Russell 2000 was up nearly 15 points for the week, or 1.9%.
The S&P downgrade was rumored all day on Friday after France confirmed during market hours and officially came after the bell. France, along with Austria, lost their triple-A rating while 7 other countries had their debt downgraded, including Spain, Italy and Portugal which were rated as “junk”. Germany kept is triple-A rating.
The weakness on Friday’s open was to be expected but the rebound off the lows was impressive as the bulls managed to save the week. Obviously, the impact could have been so much worse but it seems to say that Wall Street and the bulls are getting tired of hearing S&P cry “Europe wolf”. We mentioned in mid-December (and before the talking heads and pros) that the market was decoupling from Europe’s woes and this was apparent again on Friday ahead of a long 3-day weekend.
Of course, Greece is still an issue and could default but that is a story we will cover later in the week.
The market will likely move on earnings news this week as 4Q season kicks into second gear. It will be a big test for Tech and Banks which have some heavy-hitters coming to the plate. We cover and highlight in Bold what stocks could move the market in our Earnings section below.
The charts are showing one last possible push to resistance and the indexes could get there on better-than-expected numbers. Even if the big-name corporations can just match expectations, the market could test the July 2011 highs before pulling back for a breather.
However, if there is a high-profile earnings miss or more negative European rhetoric, a test back to support could come sooner than the bulls want.
= = = = = = = = = = = = = = =
Key of Technicals Used In Following Articles
2. Halozyme Therapeutics (HALO) – Ready to Pop or Drop?
By Michael Bryant
Halozyme Therapeutics (HALO, $9.80, down $0.06) develops recombinant human enzymes targeting the extracellular matrix to treat diabetes, cancer, and other diseases. The matrix, located outside the cell, provides structural support in tissues and directs cell migration, signaling, and survival. The company alters the matrix via enzymes to treat diseases and has a number of product candidates in its pipeline that target unmet medical areas. Below is a snapshot of their product candidates and in which phase of testing they are in.
Their primary technology Hylenex®, or rHuPH20, is an enzyme based on a synthetic version of hyaluronidase that temporarily degrades hyaluronan, a major component of skin and cartilage as well as abnormal tissues, such as tumors. The FDA approved enzyme allows easier diffusion of other drugs and fluids where the compound is injected, which then enters circulation through the matrix. The compound is rapidly inactivated in the body.
Analog Insulin – PH20, or altered insulin, is part of the company’s Ultrafast Insulin program, which combines rHuPH20 with already approved mealtime analog insulin. This results in more rapidly absorbed and faster-acting insulin with a shorter duration of effect and greater consistency from dose to dose. It is in Phase II trials for the treatment of diabetes mellitus.
PEGPH20 increases the half-life of rHuPH20 in the blood, where the compound itself does not survive. Certain cancers, including pancreatic, breast, colon and prostate, have been shown to accumulate high levels of hyaluronan. Thus, the compound can travel to the cancer site and help the dispersal of cancer treatment.
HTI-501, a recombinant human cathepsin L, a type of lysosomal protein, acts by degrading collagen, is present in high amounts in the extracellular matrix as collagen fibers. The compound is being tested to smooth the dimpled appearance of the skin by cutting and releasing the tension caused by the fibers connecting the dermis of the skin with the connective tissue that surrounds muscles, groups of muscles, blood vessels, and nerves. The compound also has the potential to treat medical conditions involving collagen, such as frozen shoulder, Dupuytren’s contracture, Peyronie’s disease, keloids, and hypertrophic scarring.
Halozyme Therapeutics partnerships with Baxter, Roche, ViroPharma, and Intrexon center around its Hylenex® Technology. Roche partners to make Herceptin®, MabThera®, and Actemra®. Baxter partners to make HyQ. ViroPharma partners to make Cinryze®. And Intrexon partners to make Alpha 1-Antitrypsin.
Last October, the company and partner Roche announced positive phase III results of Herceptin® in women with early HER2-positive breast cancer, causing the stock to surge. Each year about 1.4 million new cases of breast cancer are diagnosed worldwide, and over 450,000 people will die of the disease annually. Roche plans to file approval for both Herceptin® and MabThera®, which is also in phase III studies, in Europe during 2012 and expects to launch them in 2013. Both treatments reduced dosing time compared to the current treatment. These two products could bring significant near-term value to the company.
HyQ developed with Baxter (BAX) is expecting U.S. and European launch also in 2012. The drug is estimated to have a worldwide market value of $6 billion. The company will receive milestones and royalty payments.
Halozyme Therapeutics has also announced positive phase II data regarding the safety, pharmacokinetics and pharmacodynamics of Cinryze® with partner ViroPharma (VPHM). Positive results were seen in subjects with hereditary angioedema, a rare, debilitating and potentially fatal genetic disease.
Much of the company’s total revenue comes from collaborative agreements while the remainder comes from product sales. The graphs below show the trend in revenue and earnings. Analysts’ estimates are included despite that the company is not releasing 4th quarter (12/11) earnings until March 10th.
Analysts seem to expect revenue and earnings to fall sharply but we think they are underestimating the company’s product line and partnerships.
The stock doesn’t look cheap with price/sales of 17.87 and a price/book of 37.63, but that is not uncommon among young biotech companies. Revenue is $57.25 million, implying that the price/revenue is $0.56. But cash is $66.33 million, debt is zero, and current ratio is 5.58. The high current ratio shows that the company has plenty of current assets to cover current liabilities. And given the possibility of more licensing deals given the promise of rHuPH20, the company could be an attractive takeover target.
At $9.80, the stock is slightly below its low target of $10.00 made by the 7 analysts recorded by Thomson/First Call. Mean and medium targets are $13.00, and high target is $17.00. Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.4, unchanged from a week ago.
|
|
Current Month |
Last Month |
Two Months Ago |
Three Months Ago |
|
Strong Buy |
5 |
6 |
6 |
6 |
|
Buy |
3 |
3 |
3 |
2 |
|
Hold |
0 |
0 |
0 |
1 |
|
Underperform |
0 |
0 |
0 |
0 |
|
Sell |
0 |
0 |
0 |
0 |
Heavy insider buying indicates that insiders, besides analysts, like the stock although the technicals seem to point otherwise.
= = = = = = = = = = = = = = =
3. Earnings
The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter. If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are as of Friday’s close, 1/13/12).
TUESDAY
Check Point Software Technologies (CHKP, $50.90, down $1.43), Citigroup (C, $30.74, down $0.86), Cree (CREE, $22.90, down $0.92), Delta Air Lines (DAL, $8.85, down $0.02), Forest Laboratories (FRX, $30.90, down $0.44), Groupon (GRPN, $19.15, down $0.11, Lee Enterprises (LEE, $0.74, down $0.01), McMoRan Exploration (MMR, $12.74, down $0.74), New Oriental Education & Technology Group (EDU, $25.22, up $0.64), Northwest Pipe (NWPX, $22.02, down $0.49), Origin Agritech (SEED, $2.61, down $0.07), Park Sterling (PSTB, $4.28, down $0.05), TD Ameritrade Holding (AMTD, $16.30, Down $0.36), Tessco Technologies (TESS, $16.00, up $0.05), Wells Fargo (WFC, $29.61, Flat)
WEDNESDAY
Adtran (ADTN, $31.35, down $0.18), Bank Of New York Mellon (BK, $21.45, down $0.31), Charles Schwab (SCHW, $12.156, down $0.31), Clarcor (CLC, $50.83, down $0.61), eBay (EBAY, $30.62, down $0.96), F5 Networks (FFIV, $106.78, down $4.03), Fastenal (FAST, $46.59, up $0.73), Goldman Sachs (GS, $98.96, down $2.25), Kinder Morgan Energy Partners (KMP, $83.18, up $0.51), Plexus (PLXS, $32.35, down $1.43), PNC Financial Services Group (PNC, $61.73, down $0.36), Sify Technologies (SIFY, $4.70, down $0.05), SLM (SLM, $13.64, down $0.06), State Street (STT, $42.94, down $0.67), Western Digital (WDC, $33.35, down $0.51), Xilinx (XLNX, $32.99, down $0.47)
THURSDAY
Advanced Micro Devices (AMD, $5.66, down $0.16), American Express (AXP, $49.76, up $0.11), Bank of America (BAC, $6.61, down $0.18), BB&T (BBT, $27.23, up $0.18), BlackRock (BLK, $186.57, down $0.49), Capital One Financial (COF, $48.89, up $0.49), Digi International (DGII, $11.85, down $0.10), EZCorp (EZPW, $27.30, up $0.57), Fairchild Semiconductor International (FCS, $12.92, down $0.21), Freeport McMoRan Copper & Gold (FCX, $42.00, down $0.45), Google (GOOG, $624.99, down $4.65), Huntington Bancshares (HBAN, $5.97, Flat), Intel (INTC, $25.14, down $0.61), Interactive Brokers Group (IBKR, $15.24, down $0.01), International Business Machines (IBM, $179.16, down $1.39), Intuitive Surgical (ISRG, $459.44, up $1.31), J&J Snack Foods (JJSF, $51.55, down $0.89), Johnson Controls (JCI, $35.05, down $0.05), NetScout Systems (NTCT, $16.40, down $0.10), PPG Industries (PPG, $87.52, down $0.48), Rockwell Collins (COL, $57.15, down $0.35), Skyworks Solutions (SWKS, $17.64, down $0.34), Southwest Airlines (LUV, $8.84, down $0.13), Union Pacific (UNP, $109.73, down $1.32), UnitedHealth Group (UNH, $52.70, down $0.17)
FRIDAY
Comerica (CMA, $52.70, up $0.18), First Horizon National (FHN, $8.86, down $0.06), General Electric (GE, $18.84, down $0.09), Northwest Bancshares (NWBI, $12.71, down $0.09), Schlumberger (SLB, $67.99, down $1.71), Suntrust Banks (STI, $20.80, down $0.25)
= = = = = = = = = = = = = = =
4. Weekly Wrap Covered Call Portfolio Update (Closing prices as of 1/13/12)
We have quite a few positions that could get called away this week as the January options expire on Friday: SGMS, AA, VVUS, F, CLNE, SZYM, DNDN, MGM.
TiVo (TIVO, $10.44, up $0.16)
February 10 calls (TIVO120218C00010000, $0.80, up $0.15)
Original Entry Price: $10.29 (1/12/12)
Lowered Price from Selling Options: $9.54
Exit Target: $15
Return: 9%
Stop Target: None
Action: TiVo has traded in a tight $9-$11 range for over a year as you can tell from this weekly chart and could breakout to new highs this year. The current 52-week high is $12.65 which would be challenged if $11 is cleared. Near-term support is at $10.
We recommended buying the stock at $10.29 on 1/12/2012 and for every 100 shares to sell the February 10 calls for 75 cents. This lowered the cost basis to $9.54.
If shares are called-away by mid-February at $10 the trade makes 5%.
Patriot Coal (PCX, $7.87, down $1.15)
February 10 calls (PCX120218C00010000, $0.15, down $0.30)
Original Entry Price: $8.91 (1/12/12)
Lowered Price from Selling Options: $8.51
Exit Target: $15
Return: -8%
Stop Target: None
Action: We mentioned on Thursday when we got into the trade Wall Street was out-of-favor with this sector and shares of Patriot got whacked on Friday, falling over 12%. The company plans to take a few plants off-line until demand picks back up. We don’t mind because we plan on owning this one for a few months and the bottom is nearly in. Support is at $7.
We recommended buying the stock at $8.91 on 1/12/2012 and for every 100 shares to sell the February 10 calls for 40 cents. This lowered the cost basis to $8.51.
If shares are called-away by mid-February at $10 the trade makes 16%.
Scientific Games (SGMS, $11.19, down $0.15)
January 10 calls (SGMS120121C00010000, $1.20, down $0.05)
Original Entry Price: $9.89 (1/4/12)
Lowered Price from Selling Options: $9.44
Exit Target: $15
Return: 19%
Stop Target: None
Action: Shares started the week gaining 3% and traded up to $10.85 on Monday. On Tuesday, the stock made a run past $11 to set a new 52-week high of $11.44 which was broke with Friday’s intraday pop to $11.55. We said there was a good possibility the stock would break the prior 52-week high of $11.27 which now puts $12 on the map. Support is at $11 followed by $10 but we will likely get called away this Friday.
We recommended buying the stock at $9.89 on 1/4/2012 and for every 100 shares to sell the January 10 calls for 45 cents. This lowered the cost basis to $9.44.
If shares are called-away by mid-January at $10 the trade makes 6%.
Zynga (ZNGA, $8.87, up $0.42)
February 10 call (ZNGA120218C00010000, $0.40, up $0.10)
Original Entry Price: $9.37 (12/22/11)
Lowered Price from Selling Options: $8.87
Exit Target: $15
Return: 0%
Stop Target: None
Action: Zynga ended Monday’s session at new lows after falling to $8 on the close. Shares made up a little ground by Friday and ended above $8.75 which was what we wanted to see. We would like a close back above $9.50 this week. The company is stealing a lot of Electric Arts’ employees which could be a sign.
We recommended buying the stock at $9.37 on 12/22/11.
On 1/4/12 we recommended selling the February 10 call option for $0.50 which lowered the cost basis to $8.87.
If shares are called-away by mid-February at $10 the trade makes 13%.
Bank of America (BAC, $6.61, down $0.18)
March 6 call (BAC120317C00006000, $0.92, down $0.12)
Original Entry Price: $5.35 (12/22/11)
Lowered Price from Selling Options: $4.99
Exit Target: $7.50
Return: 32%
Stop Target: None
Action: Bank of America made an incredible run last week after starting at $6.18 and hitting a high of $7.02 on Thursday. The next wave of resistance will come in at $7.50. The company will report earnings on Thursday and support is at $6, followed by $5.50, if there is a pullback.
We recommended buying the stock at $5.35 on 12/22/11.
On 1/4/12 we recommended selling the March 6 call option for $0.36 which lowered the cost basis to $4.99.
If shares are called-away by mid-March at $6 the trade makes 20%.
Update: We recommended buying the stock again at $6.75 on 1/12/12. We are waiting for the above trade to close before selling a call option.
Vivus (VVUS, $12.20, down $0.03)
January 11 calls (VVUS120121C00011000, $1.20, down $0.17)
Original Entry Price: $10.29 (12/16/11)
Lowered Price from Selling Options: $9.39
Exit Target: $15
Return: 30%
Stop Target: None
Action: Vivus set a 52-week high of $12.84 last Thursday and added 20% for the week on news its obesity drug, Qnexa, will get special labeling. The FDA asked the company to remove the “contraindication” for women of childbearing potential contained in the proposed label. The drug would remain contraindicated for women who are pregnant or who can have children. A contraindication typically indicates that a drug should not be taken because of the health risk that clearly outweigh the benefits.
The next level of resistance will come at $15 and you can see the potential for the stock if Qnexa gets approved. Support is at $10 and we should know something by late February which is why we added to the position.
We recommended buying the stock at $10.29 on 12/16/11 and for every 100 shares to sell the January 11 calls for 90 cents. This lowered the cost basis to $9.39.
If shares are called-away by mid-January at $11 the trade makes 17%.
Update: We recommended buying the stock again at $12.60 on 1/12/12. We are waiting for the above trade to close before selling a call option.
Ford Motor (F, $12.04, down $0.10)
January 11 calls (F120121C00011000, $1.04, down $0.15)
Original Entry Price: $10.38 (12/16/11)
Lowered Price from Selling Options: $10.15
Exit Target: $14+
Return: 19%
Stop Target: None
Action: Our upside target was $12.50 last week which was just above resistance and the 200-day and 40-week MA. Shares traded up to $12.18 on Wednesday and Thursday which could be a short-term top. If not, a march to $14 could be coming. Near-term support is at $11 so we should get called away on this trade on Friday.
We recommended buying the stock at $10.38 on 12/16/11 and for every 100 shares to sell the January 11 calls for 23 cents. This lowered the cost basis to $10.15.
If shares are called-away by mid-January at $11 the trade makes 8%.
Alcoa (AA, $9.80, down $0.13)
January 9 calls (AA120121C00009000, $0.80, down $0.15)
Original Entry Price: $8.90 (12/16/11)
Lowered Price from Selling Options: $8.45
Exit Target: $11
Return: 16%
Stop Target: None
Action: Shares made a run at $10 last week and traded up to $9.97 before pulling back a little on Friday. Our longer-term price target is $12.50 which is home of the 40-weel MA if $10 is cleared and holds as support. Short-term support is at $8.50 and as long as $9 holds we will get exercised. We added to this position on Thursday.
We recommended buying the stock at $8.90 on 12/16/11 and for every 100 shares to sell the January 9 calls for 45 cents. This lowered the cost basis to $8.45.
If shares are called-away by mid-January at $9 the trade makes 7%.
Update: We recommended buying the stock again at $9.65 on 1/12/12. We are waiting for the above trade to close before selling a call option.
Clean Energy Fuels (CLNE, $13.35, down $0.27)
January 14 calls 2012 (CLNE120121C00014000, $0.15, down $0.10)
Original Entry Price: $11.47 (11/23/11)
Lowered Price from Selling Options: $11.02
Exit Target: $15
Return: 21%
Stop Target: None
Action: Shares hit a high of $14.10 last week after taking out the 200-day MA. Support is strong at $12 and the 50-day MA (not shown) of $12.40. The 40-week MA is at $13.25. If $13 holds early in the week then there is a chance another run at $14 could come by Friday which would get the calls in-the-money. Our near-term target is $16, $19 longer-term.
For those of you just joining us, Clean Energy is the leader of natural gas vehicle fueling and the company’s Natural Gas Highway initiative continues to expand in cities throughout the country.
We recommended buying the stock at $11.47 on 11/23/11 and for every 100 shares to sell the January 14 calls for 45 cents. This lowered the cost basis to $11.02.
If shares are called-away by mid-January at $14 the trade makes 27%.
Darling International (DAR, $13.85, flat)
January 15 calls 2012 (DAR120117C00015000, $0.05, flat)
Original Entry Price: $13.23 (11/23/11)
Lowered Price from Selling Options: $12.73
Exit Target: $15
Return: 9%
Stop Target: None
Action: Darling had a good week as shares moved above their 50-day MA ($13.53). We mentioned last week a test to $14 was coming and Thursday’s peak was $13.95. Support is strong at $13. Notice the tight trading range shares have been in since October and a breakout could be coming. Our near-term target is $16.
We recommended buying the stock at $13.23 on 11/23/11 and for every 100 shares to sell the January 15 calls for 50 cents. This lowered the cost basis to $12.73.
If shares are called-away by mid-January at $15 the trade makes 18%.
Symantec (SYMC, $15.88, down $0.20)
January 17.50 calls 2012 (SYMC120121C00017500, $0.02, flat)
Original Entry Price: $15.60 (11/23/11)
Lowered Price from Selling Options: $15.30
Exit Target: $18
Return: 4%
Stop Target: None
Action: Symantec traded up to $16.42 on Thursday and closed just below the 50-day MA ($16.06). The 200-day MA is at $17.64 and the 40-week MA is at $17.56. Multi-year support at $15.50 remains solid.
We recommended buying the stock at $15.60 on 11/23/11 and for every 100 shares to sell the January 17.50 calls for 30 cents. This lowered the cost basis to $15.30.
If shares are called away by mid-January at $17.50 the trade makes 14%.
Solazyme (SZYM, $10.56, down $0.51)
January 12.50 call (SZYM120121C00012500, $0.0.05, down $0.10)
Original Entry Price: $11.16 (11/14/11)
Lowered Price from Selling Options: $10.06
Exit Target: $15
Return: 5%
Stop Target: None
Action: Shares fell nearly 5% on Friday and below the 50-day MA ($11.35) for the week. There is further help at $9.50 but we are looking for current levels to hold.
We recommended buying the stock at $11.16 on 11/14/11 and for every 100 shares to sell the December 12.50 calls for 60 cents. This lowered the cost basis to $10.56.
On 1/4/12 we recommended selling the January 12.50 call option for $0.50 which lowered the cost basis to $10.06.
If shares are called-away by mid-January at $12.50 the trade makes 24%.
Dendreon (DNDN, $14.03, up $0.24)
January 10 call (DNDN120121C00010000, $4.15, up $0.20)
Original Entry Price: $9.95 (10/26/11)
Lowered Price from Selling Options: $8.45
Exit Target: $12+
Return: 66%
Stop Target: None
Action: Dendreon traded to a high of $14.66 last week and we mentioned a break above $12.50 would be super bullish. Prior resistance at $12.50 should serve as near-term support with $10 as backup but we should be getting exercised on this one come Friday.
We recommended buying the stock at $9.95 on 10/26/11 and for every 100 shares to sell the November calls for $1. This lowered the cost basis to $8.85.
On 11/23/11 we recommended selling the January 10 call option for $0.50 which lowered the cost basis to $8.45.
If shares are called-away by mid-January at $10 the trade makes 18%.
MGM Resorts (MGM, $12.35, up $0.22)
January 11 call (MGM120121C00011000, $1.35, up $0.20)
Original Entry Price: $11.73 (8/12/11)
Lowered Price from Selling Options: $9.28
Exit Target: $12+
Return: 33%
Stop Target: None
Action: MGM surged another 10% last week and traded to a high of $12.40 on Friday. Shares made a strong move past the 200-day MA ($11.94) and the 40-week MA which should serve as short-term support. The move clears the way for a run at $15 but we will be out of this trade come Friday unless shares fall off a cliff. The good news is we suggested buying another position last week.
We recommended buying the stock at $11.73 on 8/12/11 and for every 100 shares to sell the September 12 calls for 90 cents. This lowered the cost basis to $10.83.
On 9/20/11 we recommended selling the October 12 call option for $0.60 which lowered the cost basis to $10.23.
On 10/26/11 we recommended selling the November 11 call option for $0.50 which lowered the cost basis to $9.73.
On 11/23/11 we recommended selling the January 11 call option for $0.45 which lowered the cost basis to $9.28.
If shares are called-away by mid-January at $11 the trade makes 19%.
Update: We recommended buying the stock again at $11.76 on 1/12/12. We are waiting for the above trade to close before selling a call option.
Newpark Resources (NR, $9.29, down $0.17)
Original Entry Price: $9.45 (7/27/11)
Lowered Price from Selling Options: $8.10
Exit Target: $10+
Return: 15%
Stop Target: None
Action: Shares hit a 52-week high of $10.62 on Tuesday but dropped like a rock afterwards. Prior resistance was at $9.75-$10 which has opened the door for a test back down to $8.50 which is the 40-week MA. Earnings are not due out until mid-February so we were a little puzzled by the drop. A run back over $10 would be nice to see this week.
We recommended buying the stock at $9.45 on 7/27/11 and for every 100 shares to sell the August 10 calls for 50 cents. This lowered the cost basis to $8.95.
On 9/15/11 we recommended selling the December 10 call option for $0.85 which lowered the cost basis to $8.10.
Trades on HOLD: Rambus (RMBS, $8.00, down $0.28), Rare Element Resources (REE, $5.87, down $0.23), AKS Steel Holding (AKS, $9.11, down $0.42), American Capital (ACAS, $7.36, up $0.01), DryShips (DRYS, $2.19, down $0.10)
= = = = = = = = = = = = = = =
5. Week Ahead
The economic calendar starts off on Tuesday with Weekly Chain Store Sales but the bigger news will be the New York Empire Manufacturing numbers which are due out an hour before the bell.
On Wednesday, before the bell, the latest MBA Mortgage Purchase Index figures will be released along with the Producer Price Index (PPI) numbers which could pack a punch as it measures prices for goods at the wholesale level. Industrial Production and the Capacity Utilization reports are also due out before the open followed by the NAHB Housing Market Index 30 minutes after the start of trading.
Thursday brings the usual updates on Initial and Continuing Claims and the Consumer Price Index is also due out. Housing Starts and Building Permits will also be announced before Wall Street opens, followed by the Philly Fed Survey and crude inventories. Earnings could also play a big role on which way the market sways.
Friday wraps up with Existing Home Sales.























